Hyoscine butylbromide mode of action on bowel motility: From pharmacology to clinical practice
| dc.contributor.author | Corsetti, Maura | |
| dc.date.accessioned | 2024-02-07T11:56:35Z | |
| dc.date.available | 2024-02-07T11:56:35Z | |
| dc.date.issued | 2023 | |
| dc.identifier.citation | Corsetti, M., Forestier, S. and Jimenez, M. (2023) 'Hyoscine butylbromide mode of action on bowel motility: From pharmacology to clinical practice', Neurogastroenterology & Motility, 35(4), pp. e14451. doi: 10.1111/nmo.14451 https://doi.org/10.1111/nmo.14451. | en_US |
| dc.identifier.issn | 1365-2982 | |
| dc.identifier.issn | 1350-1925 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12904/18217 | |
| dc.description.abstract | BACKGROUND: Hyoscine butylbromide (HBB) has been available for use as an antispasmodic since 1951 and is indicated for the treatment of abdominal pain associated with cramps. A previous review in 2007 summarized the evidence on the mode of action of HBB in vitro and in vivo in both animal and human studies. However, since then, novel publications have appeared within the literature and also our knowledge of what represents normal motility in humans has evolved. PURPOSE: This review is the result of the collaboration between a basic scientist and clinicians with the aim of providing an updated overview of the mechanisms of action of HBB and its clinical efficacy to guide not only use in clinical practice, but also future research. Copyright © 2022 The Authors. Neurogastroenterology & Motility published by John Wiley & Sons Ltd. | |
| dc.description.uri | https://doi.org/10.1111/nmo.14451 | en_US |
| dc.language.iso | en | en_US |
| dc.subject | Abdominal pain | en_US |
| dc.subject | Hyoscine butylbromide | en_US |
| dc.title | Hyoscine butylbromide mode of action on bowel motility: From pharmacology to clinical practice | en_US |
| dc.type | Article | en_US |
| rioxxterms.funder | Default funder | en_US |
| rioxxterms.identifier.project | Default project | en_US |
| rioxxterms.version | VoR | en_US |
| rioxxterms.versionofrecord | 10.1111/nmo.14451 | en_US |
| rioxxterms.type | Journal Article/Review | en_US |
| refterms.dateFCD | 2024-02-07T11:56:36Z | |
| refterms.versionFCD | VoR | |
| refterms.dateFOA | 2024-02-07T11:56:36Z | |
| refterms.panel | Unspecified | en_US |
| html.description.abstract | BACKGROUND: Hyoscine butylbromide (HBB) has been available for use as an antispasmodic since 1951 and is indicated for the treatment of abdominal pain associated with cramps. A previous review in 2007 summarized the evidence on the mode of action of HBB in vitro and in vivo in both animal and human studies. However, since then, novel publications have appeared within the literature and also our knowledge of what represents normal motility in humans has evolved. PURPOSE: This review is the result of the collaboration between a basic scientist and clinicians with the aim of providing an updated overview of the mechanisms of action of HBB and its clinical efficacy to guide not only use in clinical practice, but also future research. Copyright © 2022 The Authors. Neurogastroenterology & Motility published by John Wiley & Sons Ltd. | en_US |
| rioxxterms.funder.project | 94a427429a5bcfef7dd04c33360d80cd | en_US |
